Cargando…

The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors

We investigated the patients with solid cancers harboring Fms-like tyrosine kinase 3 (FLT3) amplification using targeted sequencing of tumor tissue specimen and FISH assay. Simultaneously, FLT3-amplified patient-derived cells (PDCs) were generated to evaluate the sensitivity to FLT3 inhibition. A pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Sung Hee, Kim, Sun-Young, Kim, Kyung, Jang, Hyojin, Ahn, Soomin, Kim, Kyoung-Mee, Kim, Nayoung K.D., Park, Woongyang, Lee, Su Jin, Kim, Seung Tae, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Lee, Se-Hoon, Lim, Ho Yeong, Park, Keunchil, Kang, Won Ki, Lee, Jeeyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356878/ https://www.ncbi.nlm.nih.gov/pubmed/27906677 http://dx.doi.org/10.18632/oncotarget.13700

Ejemplares similares

Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center’s experiences
por: Cho, Minho, et al.
Publicado: (2017)

The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors
por: Kim, Hana, et al.
Publicado: (2021)

Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy
por: Kim, Seung Tae, et al.
Publicado: (2017)

The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs
por: Kim, Seung Tae, et al.
Publicado: (2016)

Low Frequency and Variability of FLT3 Mutations in Korean Patients with Acute Myeloid Leukemia
por: Bang, Soo-Mee, et al.
Publicado: (2008)

Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors
por: Kim, Hana, et al.
Publicado: (2021)

Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis
por: Kim, Seung Tae, et al.
Publicado: (2017)

Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy
por: Kim, Seung Tae, et al.
Publicado: (2017)

Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer
por: Hong, Jung Yong, et al.
Publicado: (2020)

Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer
por: Jung, Ki Sun, et al.
Publicado: (2017)

Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing
por: Hyung, Sujin, et al.
Publicado: (2022)

The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC)
por: Heo, Mi Hwa, et al.
Publicado: (2017)

First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients
por: Kim, Seung Tae, et al.
Publicado: (2020)

Gastrointestinal malignancies harbor actionable MET exon 14 deletions
por: Lee, Jeeyun, et al.
Publicado: (2015)

Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line
por: Kim, Seung Tae, et al.
Publicado: (2018)

Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation
por: Lee, Taehyang, et al.
Publicado: (2018)

The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer
por: Kim, Seung Tae, et al.
Publicado: (2018)

Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer
por: Yi, Jun Ho, et al.
Publicado: (2014)

To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients
por: Lee, Hansang, et al.
Publicado: (2016)

Increased sFlt-1 to PlGF Ratio in Women Who Subsequently Develop Preeclampsia
por: Kim, Shin-Young, et al.
Publicado: (2007)

Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients
por: Kim, Seung Tae, et al.
Publicado: (2015)

Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers
por: Lee, Su Jin, et al.
Publicado: (2020)

The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis
por: Kim, Seung Tae, et al.
Publicado: (2015)

The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer
por: Kim, Seung Tae, et al.
Publicado: (2017)

Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era
por: Kim, Seung Tae, et al.
Publicado: (2016)

Patient-derived cell models as preclinical tools for genome-directed targeted therapy
por: Lee, Ji Yun, et al.
Publicado: (2015)

Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial
por: Lim, Sung Won, et al.
Publicado: (2018)

Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion
por: Kim, Sun Young, et al.
Publicado: (2017)

The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer
por: Lee, Su Jin, et al.
Publicado: (2018)

Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs
por: Cho, Jang Ho, et al.
Publicado: (2019)

MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines
por: Kim, Jung Eun, et al.
Publicado: (2017)

The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma
por: Yoon, Sang Eun, et al.
Publicado: (2019)

MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer
por: Ko, Jihoon, et al.
Publicado: (2022)

Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer
por: Kim, Jinchul, et al.
Publicado: (2021)

The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs
por: Kim, Hee Kyung, et al.
Publicado: (2017)

Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia
por: Kim, Shin-Young, et al.
Publicado: (2008)

Changes in the Mean Corpuscular Volume after Capecitabine Treatment Are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer
por: Jung, Hyun Ae, et al.
Publicado: (2015)

Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer
por: Lim, Taekyu, et al.
Publicado: (2011)

Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment
por: Song, Haa-Na, et al.
Publicado: (2016)

Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer
por: Kim, Seung Tae, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ehtvgsk35v72pvu80a862ld9ul